PDF(Pubmed)
Abstract：
UNASSIGNED: Anti-obesity medications (AOMs) may provide a viable option for obesity management. However, little is known about the use of AOMs in persons with SCI/D.
UNASSIGNED: Describe health care providers\' (HCPs) views about barriers to AOM use in persons living with SCI/D.
UNASSIGNED: Descriptive qualitative design using in-depth interviews Descriptive statistics were used to calculate demographic and employment characteristics. Interviews were audio-recorded and transcribed verbatim. Transcripts were coded and analyzed using Braun and Clarke\'s (2006) six thematic analysis phases.
UNASSIGNED: HCPs (n = 12) were from 11 different nationwide facilities. Most HCPs were male (75%), a large majority were white (67%), and most were 26-49 years of age. Participants were dietitians (75%), physicians (17%), and psychologists (8%). HCPs ranged from 1.5 to 15 years of providing SCI/D care. HCPs described four main thematic barriers to AOM use in persons with SCI/D: (1) AOM side effects that are especially concerning in persons with SCI/D; (2) AOMs contribute to poor eating habits; (3) availability, accessibility, and administration; and (4) lack of evidence, clinical agreement, and knowledge about AOM use in the SCI/D population.
UNASSIGNED: There are several potential barriers to AOM use in the SCI/D population. Barriers include AOM side effects which may cause or exacerbate conditions that are already concerns in persons with SCI/D, such as bowel and skin problems, and muscle loss. SCI/D HCPs reported a lack of evidence about AOM use in persons with SCI/D, but interest in obtaining more knowledge.
UNASSIGNED: Describe health care providers\' (HCPs) views about barriers to AOM use in persons living with SCI/D.
UNASSIGNED: Descriptive qualitative design using in-depth interviews Descriptive statistics were used to calculate demographic and employment characteristics. Interviews were audio-recorded and transcribed verbatim. Transcripts were coded and analyzed using Braun and Clarke\'s (2006) six thematic analysis phases.
UNASSIGNED: HCPs (n = 12) were from 11 different nationwide facilities. Most HCPs were male (75%), a large majority were white (67%), and most were 26-49 years of age. Participants were dietitians (75%), physicians (17%), and psychologists (8%). HCPs ranged from 1.5 to 15 years of providing SCI/D care. HCPs described four main thematic barriers to AOM use in persons with SCI/D: (1) AOM side effects that are especially concerning in persons with SCI/D; (2) AOMs contribute to poor eating habits; (3) availability, accessibility, and administration; and (4) lack of evidence, clinical agreement, and knowledge about AOM use in the SCI/D population.
UNASSIGNED: There are several potential barriers to AOM use in the SCI/D population. Barriers include AOM side effects which may cause or exacerbate conditions that are already concerns in persons with SCI/D, such as bowel and skin problems, and muscle loss. SCI/D HCPs reported a lack of evidence about AOM use in persons with SCI/D, but interest in obtaining more knowledge.
摘要：
■抗肥胖药物（AOM）可能为肥胖管理提供可行的选择。然而,对SCI/D患者使用AOM的情况知之甚少。
■描述医疗保健提供者（HCP）对SCI/D患者使用AOM的障碍的看法。
■使用深度访谈进行描述性定性设计使用描述性统计数据来计算人口统计学和就业特征。访谈是录音和逐字转录的。使用Braun和Clarke\（2006）的六个主题分析阶段对成绩单进行了编码和分析。
■HCP（n=12）来自11个不同的全国性设施。大多数HCP是男性（75％），绝大多数是白人(67%)，大多数年龄在26-49岁之间。参与者是营养师（75％），医生（17%），心理学家（8%）。HCP提供SCI/D护理的时间为1.5至15年。HCP描述了SCI/D患者使用AOM的四个主要主题障碍：（1）SCI/D患者特别关注的AOM副作用；（2）AOM导致不良的饮食习惯；（3）可用性，可访问性,和管理；(4)缺乏证据，临床协议,以及有关SCI/D人群中AOM使用的知识。
■在SCI/D人群中使用AOM存在若干潜在障碍。障碍包括可能导致或加剧SCI/D患者已经关注的疾病的AOM副作用，比如肠道和皮肤问题，肌肉损失。SCI/DHCP报告缺乏关于SCI/D患者使用AOM的证据，而是对获得更多知识的兴趣。
■描述医疗保健提供者（HCP）对SCI/D患者使用AOM的障碍的看法。
■使用深度访谈进行描述性定性设计使用描述性统计数据来计算人口统计学和就业特征。访谈是录音和逐字转录的。使用Braun和Clarke\（2006）的六个主题分析阶段对成绩单进行了编码和分析。
■HCP（n=12）来自11个不同的全国性设施。大多数HCP是男性（75％），绝大多数是白人(67%)，大多数年龄在26-49岁之间。参与者是营养师（75％），医生（17%），心理学家（8%）。HCP提供SCI/D护理的时间为1.5至15年。HCP描述了SCI/D患者使用AOM的四个主要主题障碍：（1）SCI/D患者特别关注的AOM副作用；（2）AOM导致不良的饮食习惯；（3）可用性，可访问性,和管理；(4)缺乏证据，临床协议,以及有关SCI/D人群中AOM使用的知识。
■在SCI/D人群中使用AOM存在若干潜在障碍。障碍包括可能导致或加剧SCI/D患者已经关注的疾病的AOM副作用，比如肠道和皮肤问题，肌肉损失。SCI/DHCP报告缺乏关于SCI/D患者使用AOM的证据，而是对获得更多知识的兴趣。
